The S&P BSE Sensex ended the session at 25,342, up 3 points while the Nifty50 closed at 7,738 points.
The USTR has placed India on its "priority watch" list for two years in a row, saying the country's patent laws unfairly favour local drug makers.
Investors indulged in profit booking at attractive and higher valuations
The Supreme Court had rejected the company's plea for a patent on cancer drug Glivec in April.
If we are to realise the full potential of biologics' ability to improve people's health, it is essential to encourage public policy and support R&D.
The Sensex closed down 308 points at 24,894 and the Nifty has lost 96 points at 7,559.
Among the companies likely to sign deals with Gilead are Cadila, Hetero, Strides Arcolab and Mylan, while Cipla is expected to earn active pharmaceutical ingredient rights.
The S&P BSE Sensex ended down 371 points at 24,966 and the Nifty50 closed 101 points lower at 7,615.
India had been engaged in a contentious battle with the US over the issue, especially in the pharmaceutical sector.
Ajit Mishra, vice president, Research, Religare Broking, answers your queries:
The 30-share Sensex ended down by 59 points at 27,027 and the 50-share Nifty slipped 7 points at 8,087.
Index heavyweight RIL surged 3% to end above Rs 1,000 mark while IT majors were also the top gainers.
Natco Pharma, Wockhardt and Marksans have rallied between 50 and 70 per cent in the year till date.
The benchmark Nifty rallied 1,000 points or 17% from 7,000 in 78 trading sessions since May 12, till date to surpass the 8,000 mark.
Indian firm to soon launch copycat of anti-breast-cancer drug.
India's IPR framework and enforcement were comparable to those in developed countries
Special 301 Report expresses concern over weak IPR laws, to conduct reviews.
Ajit Mishra, Vice President, Research, Religare Broking, answers readers' stock market queries. Ajit will offer his unbiased views on a weekly basis
Ajit Mishra, Vice President, Research, Religare Broking, answers readers's queries on stocks they own or want to buy.
Sensex ends 134.91 pts down at 28,709.87; Nifty falls 44.70 pts at 8,712.05.
Sensex rises, Nifty ends at record high; RIL shares rally.
The Nikkei share average rose 2.6% to close at 15,195.77 points, more than recouping Tuesday's losses.
Benchmark share indices ended lower for the third straight session as investors turned cautious amid tensions in Iraq even as consumer durables shares stole the limelight tracking rally in gold prices.
'Pay-for-delay' settlements between drug patent-holders and generics manufacturers to delay the launch of cheaper generic medicine are increasingly being scrutinised by antitrust regulators
It will now take at least two more years to get a clarity on the priorities and policies of the leadership of the new state of Telangana.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances